LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serum Albumin Levels Associated with Mortality in Hemodialysis Patients

By LabMedica International staff writers
Posted on 06 Sep 2016
Image: The Hitachi 7600–210 modular clinical biochemistry analyzer (Photo courtesy of Hitachi).
Image: The Hitachi 7600–210 modular clinical biochemistry analyzer (Photo courtesy of Hitachi).
Serum albumin is commonly used as a proxy for nutritional status, as well as a marker of inflammation and a low serum albumin concentration is not only indicative of protein energy wasting in dialysis patients, but it is also a powerful predictor of the mortality risk in this population.

Several clinical conditions are associated with low serum albumin levels in dialysis patients, including infectious and inflammatory diseases, fluid overload, inadequate dialysis, severe co-morbidity, and taste change. Therefore, regular monitoring of serum albumin levels is useful for predicting outcomes in dialysis patients.

Scientists the Chang Gung University College of Medicine (Taoyuan City, Taiwan) and their colleagues included in a study 781 patients who received maintenance hemodialysis (HD) in a large, hospital-facilitated HD center. Five-year medical records (2009–2013) were retrospectively reviewed, and the cut-off level for serum albumin level was set at 3.5 g/dL. Serial haemogram results and biochemical data from the study period were collected and were analyzed retrospectively.

Corrected serum calcium was calculated and all blood samples were analyzed using commercial kits and the Hitachi 7600–210 autoanalyzer (Hitachi Ltd., Tokyo, Japan). Albumin was measured using the bromocresol green method; the normal range was 3.5–5.2 g/dL. The outcome measures included the associations between serum albumin reach rates (defined as the percentage of monthly serum albumin level recordings that were greater or equal to 3.5 g/dL) and time-averaged albumin levels in the first 2-year period with all-cause and cardiovascular mortality in the subsequent 3-year period.

The investigator found that among the 781 patients, 689 patients had higher albumin reach rates and 92 patients had lower albumin reach rates over the 5-year period. Older age and higher prevalence of diabetes were identified in the patients with lower albumin reach rates. Patients with higher albumin reach rates exhibited higher survival rates than those with lower albumin reach rates. In terms of haemogram and biophysical parameters, patients with lower albumin reach rates exhibited significantly lower values for albumin, blood urea nitrogen (BUN), creatinine (Cr), potassium (K), and phosphate (P), and higher levels of corrected serum calcium (Ca), ferritin, and cardiothoracic (CT) ratio than those with higher albumin reach rates.

The authors concluded that their study showed that a higher serum albumin level has a survival benefit in long-term HD patients. An obviously low albumin level should emphasize the need for initiating a management strategy and receiving appropriate medical intervention. The study was published on August 20, 2016, in the journal BMC Nephrology.

Related Links:
Chang Gung University College of Medicine
Hitachi
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more